FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to an antibody or fragment thereof, which specifically binds to the exposed to the extracellular medium N-terminal region of lysyl-tRNA-synthetase (KRS) and contains: a heavy chain variable region (VH) containing: complementarity-determining region 1 (CDR1) of a heavy chain comprising an amino acid sequence selected from a group consisting of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 25 and SEQ ID NO: 37; complementarity-determining region 2 (CDR2) of the heavy chain, comprising an amino acid sequence selected from SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 27 and SEQ ID NO: 39; and complementarity determining region 3 (CDR3) of heavy chain, comprising an amino acid sequence selected from SEQ ID NO: 5, SEQ ID NO: 17, SEQ ID NO: 29 and SEQ ID NO: 41; and a light chain variable region (VL) comprising: a complementarity determining region 1 (CDR1) of a light chain comprising an amino acid sequence selected from a group consisting of SEQ ID NO: 7, SEQ ID NO: 19, SEQ ID NO: 31 and SEQ ID NO: 43; complementarity-determining region 2 (CDR2) of a light chain comprising an amino acid sequence selected from SEQ ID NO: 9, SEQ ID NO: 21, SEQ ID NO: 33 and SEQ ID NO: 45; and a complementarity determining light chain region 3 (CDR3) comprising an amino acid sequence selected from SEQ ID NO: 11, SEQ ID NO: 23, SEQ ID NO: 35 and SEQ ID NO: 47, relates to a polynucleotide encoding an antibody or a fragment thereof, relates to a recombinant expression vector comprising a polynucleotide, also relates to a cell transformed with a recombinant vector, relates to a method of producing an antibody or a fragment thereof, relates to a method for specifically detecting an N-terminal region of an L-terminal region of lysyl-tRNA synthetase (KRS), relates to a pharmaceutical composition for inhibiting cancer metastasis and to a composition for preventing or treating a disease associated with migration of immune cells, also relates to a method of treating a disease associated with migration of immune cells.
EFFECT: group of inventions provides producing an antibody or a fragment thereof, specifically binding to an epitope, comprising a sequence of SEQ ID NO: 97 in N-terminal of lysyl-tRNA synthetase (KRS), where by binding to said epitope, the antibody reduced the level of KRS increased on the cell membrane of immune cells, and actually inhibited migration and infiltration of immune cells, having the effect of treating associated with such migration of diseases.
20 cl, 6 tbl, 35 dwg, 8 ex
